Alto Neuroscience (ANRO)

• Market cap: $415M
• 1 day: 0.45%
• 5 days: -8.81%
• 1 month: 9.06%
• 3 months: 239.09%
• 6 months: 365.51%
• Year to date: 205.02%
• 1 year: 202.26%
• 5 years: -35.46%
• 10 years: -35.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 76